Profile
Michael Gray serves as Chief Financial Officer and Chief Operating Officer of Upstream Bio, Inc. (UPB), a clinical-stage biotechnology company developing therapies for inflammatory diseases, including verekitug, a TSLP receptor antagonist in clinical development. In the most recent SEC filing dated January 6, 2026, Gray is listed as CFO and COO with no reported stock purchases or sales.
| Role | Insider |
|---|
| Notability | 45/100 |
|---|
Board memberships
Awards & honors
- Oversees financial planning, accounting, and reporting for UPB's clinical development programs.
- Manages operations and capital allocation to support verekitug development.
- Contributes to SEC filing accuracy and corporate governance disclosures.
Frequently Asked Questions
Who is GRAY MICHAEL?
Michael Gray serves as Chief Financial Officer and Chief Operating Officer of Upstream Bio, Inc. (UPB), a clinical-stage biotechnology company developing therapies for inflammatory diseases, including verekitug, a TSLP receptor antagonist in clinical development. In the most recent SEC filing dated January 6, 2026, Gray is listed as CFO and COO with no reported stock purchases …
How many SEC Form 4 filings has GRAY MICHAEL submitted recently?
1 primary Form 4 filings in the last 90 days, covering 1 company.
Has GRAY MICHAEL been buying or selling stock?
Recorded transactions: 0 open-market purchases () and 2 open-market sales ($13K) across all tracked filings.
Where can I see all of GRAY MICHAEL's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.